Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study. |
| |
| Authors: | M Parliament N Jha E Rapp C Smith J MacKinnon J M Nabholtz J Hanson T Reiman J Mackey |
| |
| Institution: | Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. |
| |
| Abstract: | We report a phase I/II study of weekly concurrent carboplatin and radiotherapy in patients with nasopharyngeal carcinoma (M0 stage). Of 47 patients registered, 45 completed the treatment course. Twenty-six (55%) (95% CI, 41-69%) patients experienced > or =grade 3 acute toxicity (RTOG). Five (11%) (95% CI, 2-20%) patients experienced > or =grade 3 chronic toxicity. This regimen appears to have acceptable toxicity compared to the experimental arm of Phase III Intergroup Study 0099, but progression-free and overall survival are probably inferior. At present, there is no data to suggest that carboplatin can replace cisplatin for concurrent chemoradiation for NPC. |
| |
| Keywords: | |
|
|
